SCHEDULE: Fairmount Boosts Crescent Biopharma Stake to 18.53%

Fairmount Funds Management LLC and its affiliates increased their beneficial ownership in Crescent Biopharma, Inc. to 18.53% through a $20 million private placement.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin, and Tomas Kiselak (collectively, the "Reporting Persons") have amended their Schedule 13D filing for Crescent Biopharma, Inc.
• The Reporting Persons now beneficially own an aggregate of 5,643,482 Ordinary Shares, representing 18.53% of the company's outstanding Ordinary Shares.
• This ownership includes 2,747,866 Ordinary Shares, 2,890,000 Ordinary Shares issuable upon conversion of Series A Preferred Shares, and 5,616 Ordinary Shares issuable upon exercise of Pre-Funded Warrants.
• The percentage is based on 30,452,383 Ordinary Shares outstanding as of December 8, 2025, which includes 13,664,251 Ordinary Shares issued in a private placement on December 4, 2025.
• On December 4, 2025, Fairmount Healthcare Fund II L.P. ("Fund II") purchased 1,360,000 Ordinary Shares at $13.41 per share and Pre-Funded Warrants to purchase 131,434 Ordinary Shares at $13.409 per warrant, totaling an aggregate purchase price of $19,999,998.51.
• The acquisition was made through a private investment in public equity (PIPE) transaction, which closed on December 8, 2025.
• The exercise of Pre-Funded Warrants is subject to a 9.99% beneficial ownership limitation, and the conversion of Series A Preferred Shares is subject to a 19.99% beneficial ownership limitation, which can reduce to 9.99% under certain conditions.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital infusion for Crescent Biopharma from a major institutional investor, which is generally positive for the company's financial stability and future operations. However, the transaction involves shareholder dilution and the potential for future market overhang from registered shares.

Positives

• Crescent Biopharma, Inc. received a significant capital infusion of nearly $20 million from institutional investors through the private placement.
• The investment by Fairmount Funds Management LLC and its affiliates demonstrates continued institutional confidence in Crescent Biopharma.
• The company has entered into a Registration Rights Agreement, obligating it to register the resale of the newly issued shares and warrants, providing liquidity for investors.

Negatives

• The issuance of 13,664,251 Ordinary Shares in the private placement, along with additional shares underlying warrants and preferred shares, results in dilution for existing shareholders.

Risks

• Beneficial ownership limitations on the exercise of Pre-Funded Warrants (9.99%) and conversion of Series A Preferred Shares (19.99%) may restrict the immediate full conversion or exercise by the Reporting Persons.
• The requirement for Crescent Biopharma to register the resale of the newly issued securities could lead to a market overhang, potentially impacting the share price once these shares become freely tradable.

Future Outlook

Crescent Biopharma is obligated to file an initial registration statement for the resale of the Ordinary Shares and Pre-Funded Warrants sold in the PIPE within 30 days of the closing, and to use reasonable best efforts to have it declared effective within 60 days thereafter.

Industry Context

The capital raise through a private placement is a common financing strategy for biopharma companies like Crescent Biopharma, often used to fund research and development, clinical trials, or general corporate purposes. The increased institutional ownership by Fairmount suggests a positive long-term view on the company's prospects within the competitive biotechnology sector.

Corporate Governance

Related Party Transactions

• Fairmount Healthcare Fund II L.P., managed by Fairmount Funds Management LLC (whose managing members are Peter Harwin and Tomas Kiselak, also reporting persons), participated in a private placement with Crescent Biopharma, Inc. on December 4, 2025. Fund II purchased 1,360,000 Ordinary Shares and Pre-Funded Warrants for 131,434 Ordinary Shares for approximately $20 million.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares and warrants, but the company receives capital for operations.
• Company: Benefits from a significant capital infusion to support its strategic initiatives and operations.

Next Steps

• Crescent Biopharma is required to prepare and file an initial registration statement with the SEC for the resale of the Ordinary Shares and Pre-Funded Warrants sold in the PIPE no later than 30 days following the closing (by approximately January 7, 2026).
• The company must use its reasonable best efforts to have this registration statement declared effective within 60 days after filing (by approximately March 8, 2026).

Key Dates

Recommendation

The capital raise provides essential funding for Crescent Biopharma, which is a positive development. However, the issuance of new shares and warrants results in dilution for existing shareholders. Furthermore, the upcoming registration for the resale of these securities could create a market overhang, potentially exerting downward pressure on the stock price in the short to medium term. A seasoned investor would likely hold to observe how the company deploys the newly acquired capital and how the market absorbs the additional shares once they become freely tradable, rather than making an immediate buy or sell decision based solely on this ownership update.

Keywords

Crescent Biopharma, Fairmount Funds Management, Schedule 13D, PIPE, Private Placement, Beneficial Ownership, Ordinary Shares, Pre-Funded Warrants, Series A Preferred Shares, Registration Rights, Biotechnology, Capital Raise